Bispecific antibodies (BsAbs) that redirect cytotoxic T lymphocytes (CTLs) via CD3 engagement represent a promising approach in cancer immunotherapy. Here, we explore the development of VNAR-based BsAbs for improved tumor targeting. Shark-derived VNARs possess unique properties such as small size, high stability, and antigen specificity, making them ideal candidates for T cell engagement. We immunized banded houndsharks (Triakis scyllium) with the recombinant human CD3 epsilon domain to isolate VNARs that specifically recognize CD3. The isolated anti-CD3 VNARs showed moderate affinity for recombinant human CD3 and bound to CD3+ cell lines. These results suggest the potential of these VNARs for the construction of VNAR-based BsAbs as T cell engagers, providing a novel avenue for cancer immunotherapy.